Silexion Therapeutics CORP (SLXNW) — 10-Q Filings
All 10-Q filings from Silexion Therapeutics CORP. Browse 2 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (2)
-
Silexion Boosts Cash, Equity Amidst R&D Cuts and Reverse Splits
— Nov 12, 2025 Risk: high
Silexion Therapeutics Corp (SLXNW) reported a significant increase in cash and cash equivalents to $9.243 million as of September 30, 2025, up from $1.187 milli -
Silexion Therapeutics Files 10-Q Post Reverse Split
— May 13, 2025 Risk: medium
Silexion Therapeutics Corp. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Biomotion Sciences, reported financial results aft
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX